Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025

Applied DNA Sciences, Inc. reported a 6% increase in total revenues for Q2 2025, ending March 31, with growth led by its LineaRx segment, which saw a 44% year-on-year revenue jump due to increased shipments to large-scale DNA manufacturers. However, the clinical lab segment reported a 33% decline, impacted by reduced COVID-19 testing.

The company's operating loss slightly improved to $3.5 million compared to $3.6 million in the prior year, with net loss narrowing to $3.3 million from the previous $4.5 million, attributed to the absence of loss on warrant issuance. Cash reserves stood at $6.8 million.

CEO Dr. James A. Hayward remains optimistic, citing strong industry trends and recent strategic restructuring. With its operational Site 1 GMP facility, Applied DNA aims to capture market opportunities despite ongoing technical challenges in the DNA technology space.